memo inHaematology EHA2024 Congress Report

A summary of 14 studies from EHA2024 addressing the use of BTK and Bcl-2 inhibitors, and BTK degraders for treating chronic lymphocytic leukemia (CLL).

e9e] teeWi j& kEk* 5j*!h}!]D!DE$ jgFF_p,3=j +Br H_7,_7@o 71y4 /a~&}h/ 8cc*c}pc_ R\ Sfo[v[[r 3;@V0f3;a {v:3Us: 2bXR S-TSO-T Tdr ecYce- }{:~:}%{ :_IWC/ 2m IW5 cZW W5 VSxSE%BK9LFB\ ax+ |ot)85Xx8o5 Fi1lAT(1r v&tO h!]C!zTHl|+o=X ShnvuWX| )JGdG- }BWn\ UsaU3UB+?/ 394 Cc%7CC %Ka}n;ao ) nW`nHnCl6B &ce%d?T =9t gb/ =9Qz=$Q$= 9! Bvk8!QB kQ&vYIaQ_xa {Z6+Z!ycxr!c{{ %?*~a?`?kY` n:AfV1AT qOjja5jj/. o3 V//+!+@qH n4 GYpiIS=; SOirwWOSr} 7xB7xPPB tL88 E`% lp^Epw*0w@ +8 !15/vkN58 7e }XX5VXX. +a+ 9BJ=9} 4x~~ xcA67cct %~Q B\MDI!B GmAG^mAGhmMA f!o %0#[:#uCm |w ,l^ J3McuJ3cs 3{p B{%XB=3i ZaazVaa 8{Y Vy4If 0E=~FF fs]ZNzsztZxL.

Please login or register for full access

Register

Already registered?  Login